Trial Search Results
Pulmonary Interstitial Lymphography in Early Stage Lung Cancer
Lung cancer is a common cause of morbidity and mortality, and even with modern imaging, lung cancer staging is inadequate. Involved regional lymph nodes often are not detectedand are subsequently ignored at the time of definitive surgery or radiation. This may lead to regional failures in otherwise curable patients. Our goal is to identify the primary lymph node drainage of lung cancer. With the results of this research, management could be more customized to individual patient circumstances, potentially improving outcomes.
Stanford is currently not accepting patients for this trial.
Lead Sponsor:
Stanford University
Stanford Investigator(s):
Intervention(s):
- Radiation: Stereotactic Body Radiation Therapy (SBRT)
- Radiation: Computed Tomography (CT)
- Device: Cyberknife
- Device: Trilogy
- Device: True Beam
- Drug: Iohexol
- Drug: Iodixanol
Phase:
N/A
Eligibility
INCLUSION CRITERIA
- Either:
- Established primary lung cancer/ cancer metastatic to lung, OR
- Lesion suspicious for malignancy in lung, according to the following criteria:
- Histopathologically confirmed lung cancer or cancer metastatic to lung, OR
- Plan for biopsy of suspicious lung mass based on imaging (growth on serial
CT scan or nodule/mass with focal hypermetabolism on FDG-PET scan), OR
- Known metastatic cancer, with metastases to the lung based on imaging
- Age > 18 years old
- Eastern Clinical Oncology Group (ECOG) performance status 0, 1 or 2 (Appendix IV)
- No prior surgery, chemotherapy, or radiation for the current lung tumor
EXCLUSION CRITERIA
- Prior radiotherapy to thorax
- Iodine allergy
- Contraindication to receiving radiotherapy, unless undergoing surgery
- Pregnant
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting